Kliničke studije


Bioavailability of a silybin-phosphatidylcholine complex in dogs.

Filburn CR1Kettenacker RGriffin DW. J Vet Pharmacol Ther. 2007 Apr;30(2):132-8.

Bioavailability Following Oral Administration of a Silibinin-Phosphatidylcholine Complex in CatsJournal of Applied Research in Veterinary Medicine, The 10(2):107-112 · January 2010 with 31 Reads

Am J Vet Res. 2009 Jan;70(1):57-62. Assessment of oxidative stress in leukocytes and granulocyte function following oral administration of a silibinin-phosphatidylcholine complex in cats. Webb CB, McCord KW, Twedt DC.

July 2001, Volume 15, Issue 7, pp 465-489 Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders

Arcari, M., Brambilla, A., Brandt, A., Caponi, R., Corsi, G., Di Rella, M., Solinas, F. & Wachter, W.P. (1992) [A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations].

Bollettino Chimico Farmaceutico, 131, 205–209. Barzaghi, N., Crema, F., Gatti, G., Pifferi, G. & Perucca, E. (1990) Pharmacokinetic studies on IdB 1016, a silybin–phosphatidylcholine complex, in healthy human subjects. European Journal of Drug Metabolism and Pharmacokinetics, 15, 333–338. Campos, R., Garrido, A., Guerra, R. & Valenzuela, A. (1989) Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Medica, 55, 417–419. Center, S. (2004) Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders. Veterinary Clinics Small Animal Practice, 24, 67–172. Chon, S.K. & Kim, N.S. (2005) Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitology Research, 97, 445–451. Chung, S.Y., Sung, M.K., Kim, N.H., Jang, J.O., Go, E.J. & Lee, H.J. (2005) Inhibition of P-glycoprotein by natural products in human breast cancer cells. Archives of Pharmacal Research, 28, 823–828. Comoglio, A., Leonarduzzi, G., Carini, R., Busolin, D., Basaga, H., Albano, E., Tomasi, A., Poli, G., Morazzoni, P. & Magistretti, M.J. (1990) Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex. Free Radical Research Communications, 11, 109–115. Crocenzi, F.A., Pellegrino, J.M., Sanchez Pozzi, E.J., Mottino, A.D., Garay, E.A. & Roma, M.G. (2000) Effect of silymarin on biliary bile salt secretion in the rat. Biochemical Pharmacology, 59, 1015–1022. Dehmlow, C., Erhard, J. & de Groot, H. (1996) Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology, 23, 749–754. Di Sario, A., Bendia, E., Taffetani, S., Omenetti, A., Candelaresi, C., Marzioni, M., De Minicis, S. & Benedetti, A. (2005) Hepatoprotective and antifibrotic effect of a new silybin–phosphatidylcholine–Vitamin E complex in rats. Digestive and Liver Disease, 37, 869–876. Floersheim, G.L., Eberhard, M., Tschumi, P. & Duckert, F. (1978) Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicology and Applied Pharmacology, 46, 455–462. Flora, K., Hahn, M., Rosen, H. & Benner, K. (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology, 93, 139–143. Flory, P.J., Krug, G., Lorenz, D. & Mennicke, W.H. (1980) [Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose]. Planta Medica, 38, 227–237